Latest Innovation News

Aerometrex delivered a landmark FY26 with operating revenue up 12.3% to $26.84 million and EBITDA more than doubling to $7.68 million, driven by a 27.2% jump in MetroMap subscription revenue and a 37.8% rise in Annual Contract Value.

Integrated Research’s FY26 results reveal a sharp 91% drop in net profit amid softer renewals and rising expenses, offset by a 27% jump in cash and a special dividend. The company pushes forward with AI-powered products despite early-stage commercialisation risks.

Genesis Energy posted a robust FY26 with Normalised EBITDAF up 11% to $522m, driven by margin growth and strategic investments in renewables and battery storage. A $400m equity raise bolstered its balance sheet as it accelerates New Zealand’s energy transition.

Me Today Limited delivered a 36% revenue surge to $7.96 million in FY26, cutting its EBITDA loss by 43% and locking in $1.59 million of new capital from major shareholders ahead of October warrant exercises.

Pengana Capital Group reported a statutory loss of $5.6 million for FY26 despite a 14% rise in funds under management, driven by upfront costs linked to new product launches and expanding private credit platforms.

Associate Global Partners (ASX:APL) reported a 20% rise in funds under management to $1.672 billion for FY2026, driven by strong inflows and new partnerships with Muzinich and ARK Invest.

Urbanise.com Limited reported 14.3% revenue growth to $15 million in FY2026, significantly narrowing its net loss to $0.9 million while advancing a NAB partnership pilot and launching AI features.

Resimac Group Ltd delivered a 42% jump in statutory profit for FY26 despite flat revenue, driven by strong home loan growth and improved margins, while raising its final dividend to 6 cents per share.

Ainsworth Game Technology’s first half 2026 results reveal a sharp revenue drop driven by North American and Latin American market pressures, offset partially by Asia Pacific growth and a key patent licensing deal.

The Koala Company posted a $24.6 million profit for FY26 on $332.3 million revenue, surpassing IPO forecasts with strong international growth and margin gains.

Mastermyne Group Limited (ASX:MYE) delivered a robust FY26 with revenue up 13% to $237.7 million and underlying profit before tax surging 148% to $15.7 million, supported by contract wins and a record order book.

Radiopharm Theranostics has dosed the first patient in the second cohort of its Phase 1/2a trial for RV-01, a radiopharmaceutical targeting B7-H3 expressing solid tumors, marking a key dose escalation milestone.